Mission Wealth Management LP grew its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 1.0% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 7,294 shares of the life sciences company’s stock after acquiring an additional 75 shares during the period. Mission Wealth Management LP’s holdings in Illumina were worth $2,266,000 as of its most recent SEC filing.
Several other large investors have also recently modified their holdings of the company. Proficio Capital Partners LLC raised its stake in shares of Illumina by 61.7% during the fourth quarter. Proficio Capital Partners LLC now owns 97 shares of the life sciences company’s stock valued at $29,000 after acquiring an additional 37 shares during the last quarter. Colony Group LLC raised its stake in shares of Illumina by 3.3% during the fourth quarter. Colony Group LLC now owns 1,172 shares of the life sciences company’s stock valued at $352,000 after acquiring an additional 37 shares during the last quarter. Massmutual Trust Co. FSB ADV raised its stake in Illumina by 83.0% in the fourth quarter. Massmutual Trust Co. FSB ADV now owns 86 shares of the life sciences company’s stock worth $26,000 after buying an additional 39 shares in the last quarter. Sage Capital Advisors llc raised its stake in Illumina by 0.7% in the first quarter. Sage Capital Advisors llc now owns 5,887 shares of the life sciences company’s stock worth $1,829,000 after buying an additional 40 shares in the last quarter. Finally, Sterling Investment Advisors Ltd. raised its stake in Illumina by 2.0% in the first quarter. Sterling Investment Advisors Ltd. now owns 2,090 shares of the life sciences company’s stock worth $649,000 after buying an additional 40 shares in the last quarter. 89.73% of the stock is owned by hedge funds and other institutional investors.
A number of equities analysts recently issued reports on ILMN shares. Canaccord Genuity reissued a “buy” rating and issued a $350.00 price target (down from $360.00) on shares of Illumina in a research note on Friday, April 26th. BidaskClub raised shares of Illumina from a “hold” rating to a “buy” rating in a research note on Tuesday, April 16th. Wolfe Research started coverage on shares of Illumina in a research note on Thursday, May 30th. They issued an “outperform” rating for the company. OTR Global downgraded shares of Illumina to a “positive” rating in a research note on Tuesday, April 2nd. Finally, Zacks Investment Research raised shares of Illumina from a “hold” rating to a “buy” rating and set a $339.00 price target for the company in a research note on Friday, February 22nd. Two investment analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $354.35.
Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Thursday, April 25th. The life sciences company reported $1.60 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.34 by $0.26. The business had revenue of $846.00 million for the quarter, compared to analysts’ expectations of $838.70 million. Illumina had a net margin of 25.06% and a return on equity of 23.49%. The business’s revenue was up 8.2% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.45 earnings per share. On average, equities research analysts expect that Illumina, Inc. will post 6.68 earnings per share for the current fiscal year.
In other Illumina news, SVP Omead Ostadan sold 1,260 shares of the company’s stock in a transaction dated Friday, May 10th. The shares were sold at an average price of $315.32, for a total value of $397,303.20. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, SVP Charles Dadswell sold 124 shares of the company’s stock in a transaction dated Monday, April 1st. The stock was sold at an average price of $314.45, for a total transaction of $38,991.80. Following the completion of the sale, the senior vice president now owns 8,210 shares in the company, valued at approximately $2,581,634.50. The disclosure for this sale can be found here. In the last 90 days, insiders sold 46,991 shares of company stock worth $14,643,684. Corporate insiders own 0.38% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This news story was reported by Ticker Report and is owned by of Ticker Report. If you are viewing this news story on another domain, it was copied illegally and republished in violation of international copyright and trademark legislation. The legal version of this news story can be read at https://www.tickerreport.com/banking-finance/4371499/illumina-inc-nasdaqilmn-stake-boosted-by-mission-wealth-management-lp.html.
Illumina Company Profile
Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array.
Recommended Story: What is a short straddle?
Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.